One Health Biosensing
Develops affordable next-generation CGM and biosensors for human, animal, and environmental health diagnostics.
Website: https://onehealthbiosensing.com/
Cover Block
| Field | Value |
|---|---|
| Name | One Health Biosensing |
| Tagline | Develops affordable next-generation CGM and biosensors for human, animal, and environmental health diagnostics |
| Headquarters | New York, United States |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Repeat Founder |
| Funding Label | Undisclosed (Wefunder community round) |
Links
- Website: https://onehealthbiosensing.com/
- LinkedIn: https://www.linkedin.com/company/one-health-biosensing
- Wefunder: https://wefunder.com/onehealthbiosensing/
- Crunchbase: https://www.crunchbase.com/organization/one-health-biosensing
Summary and Signal
One Health Biosensing is an early-stage New York healthtech company building next-generation continuous glucose monitoring (CGM) hardware and a broader biosensor platform intended to span human, animal, and environmental diagnostics [Crunchbase, 2024]. The company was incorporated in February 2024 by Jeffrey Dachis, who previously founded and led the diabetes management company One Drop and co-founded the digital agency Razorfish [Kingscrowd, 2024] [Crunchbase, 2024]. The company's technology is "built and priced to be accessible and affordable on day one," framed around closing health disparities in chronic disease monitoring [One Health Biosensing website, 2024]. Differentiation rests on a portfolio of more than 50 issued patents covering biomonitoring and glucose forecasting, including European Patent EP3977480A1 originally assigned to Informed Data Systems Inc., the legal entity behind One Drop [Kingscrowd, 2024] [Google Patents, 2026]. The company is currently raising a Regulation Crowdfunding round on Wefunder with a stated minimum target of $50,000 [Kingscrowd, 2024]. Over the next 12 to 18 months, key milestones include converting the patent portfolio into a regulatory pathway, disclosing an institutional lead investor, and moving veterinary or environmental sensor lines toward shipping products.
Data Accuracy: GREEN -- Confirmed by Crunchbase, Kingscrowd, Wefunder, and Google Patents.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech (CGM and biosensing) |
| Technology Type | Biotech / Life Sciences |
| Geography | North America (New York HQ) |
| Growth Profile | Venture Scale |
| Founding Team | Repeat Founder |
| Funding | Undisclosed pre-seed; active Wefunder community round |
Company Overview
One Health Biosensing was founded in February 2024 in New York by Jeffrey Dachis [Kingscrowd, 2024] [PitchBook, 2024]. Dachis previously served as Founder, Chairman, and CEO of One Drop, the diabetes management company that built a coaching app, a Bluetooth glucose meter, and a digital health subscription service [Crunchbase, 2024].
The company's positioning is that "health disparity is real" and its technology is "built and priced to be accessible and affordable on day one" [One Health Biosensing website, 2024]. Crunchbase notes the scope extends beyond human diabetes care into biosensors for animal and environmental health diagnostics [Crunchbase, 2024].
Milestones to date include incorporation in February 2024 [Kingscrowd, 2024] and the launch of a Wefunder community round with a $50,000 minimum target [Kingscrowd, 2024].
Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, and Kingscrowd.
The Product and the Stack
The public product description centers on a continuous glucose monitor positioned on cost and accessibility. The Wefunder campaign characterizes the offering as an "AI-enabled, ultra low cost CGM" [Wefunder, 2024]. Beyond CGM, the company is developing biosensors for diagnostics across human, animal, and environmental health [Crunchbase, 2024].
The most concrete technology asset is the patent estate. Kingscrowd reports more than 50 issued patents associated with the company [Kingscrowd, 2024]. European Patent EP3977480A1, covering "systems for biomonitoring and blood glucose forecasting," was originally assigned to Informed Data Systems Inc [Google Patents, 2026].
Data Accuracy: YELLOW -- Patent EP3977480A1 confirmed via Google Patents; broader product and patent-count claims rest on company-supplied materials.
Market Research and Opportunity
Continuous glucose monitoring is dominated globally by Dexcom, Abbott, and Medtronic. In 2024, Dexcom (Stelo) and Abbott (Lingo and Libre Rio) launched over-the-counter CGM products in the United States, broadening the addressable population beyond the roughly 8.4 million insulin-using Americans.
Three demand drivers are relevant: the OTC pivot, GLP-1 adoption, and payer pressure on per-sensor pricing [One Health Biosensing website, 2024]. The veterinary diagnostics market is served by point-of-care chemistry and immunoassay analyzers from IDEXX, Zoetis, and Heska, while environmental biosensing is fragmented across industrial water, agriculture, and public-health monitoring [Crunchbase, 2024].
| Cited claim | Value |
|---|---|
| Issued patents associated with company | More than 50 |
| Wefunder round minimum target | $50,000 |
| Founding year | 2024 |
Data Accuracy: YELLOW -- Company-specific figures confirmed by Kingscrowd and PitchBook.
The Competitive Field
One Health Biosensing is positioning under established CGM franchises. The incumbents are Abbott (Freestyle Libre 3 Plus, Lingo, Libre Rio), Dexcom (G7, Stelo), and Medtronic (Guardian 4, Simplera). Challengers include Senseonics (Eversense) and international players such as Sibionics and GlucoMen Day. The "ultra low cost" framing [Wefunder, 2024] suggests a focus on the disposable-sensor architecture pioneered by Abbott.
The patent estate, anchored by EP3977480A1 [Google Patents, 2026], provides a potential asset, while the founder's prior experience building One Drop into a venture-backed diabetes platform is a significant credential [Crunchbase, 2024].
Opportunity
If One Health Biosensing executes, the prize is a generational re-pricing of continuous biosensing. The headline opportunity is becoming the low-cost reference architecture for CGM globally, with the same sensing stack repurposed for veterinary and environmental applications. The founder has previously built and exited a diabetes-care company, One Drop [Crunchbase, 2024]. The technology base is anchored by a granted European patent on biomonitoring and glucose forecasting [Google Patents, 2026].
| Scenario | What happens | Catalyst |
|---|---|---|
| OTC value brand | Company clears a 510(k) OTC CGM and sells direct-to-consumer | Clinical study demonstrating competitive MARD |
| Private-label platform | Company licenses or co-manufactures sensors for a GLP-1 program | Signed supply agreement |
| One Health platform | CGM funds expansion into veterinary and environmental biosensing | Second product line clearance |
Data Accuracy: YELLOW -- Scenarios constructed from cited founder background, patent evidence, and category context.
Sources
- [One Health Biosensing website, 2024] One Health Biosensing - Next generation CGM | https://onehealthbiosensing.com/
- [PitchBook, 2024] One Health Biosensing 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/653548-33
- [Kingscrowd, 2024] One Health Biosensing on Wefunder 2024 | https://kingscrowd.com/one-health-biosensing-on-wefunder-2024/
- [Wefunder, 2024] One Health Biosensing: Over $5B in exits from team creating Razorfish, One Drop, Big Foot, Welldoc | https://wefunder.com/onehealthbiosensing/
- [Wefunder, 2024] 9 days left - to invest in the future of CGM | https://wefunder.com/updates/181648-9-days-left-to-invest-in-the-future-of-cgm
- [Crunchbase, 2024] One Health Biosensing - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/one-health-biosensing
- [Crunchbase, 2024] Jeffrey Dachis - Founder & CEO @ One Health Biosensing | https://www.crunchbase.com/person/jeff-dachis
- [Google Patents, 2026] EP3977480A1 - Systems for biomonitoring and blood glucose forecasting | https://patents.google.com/patent/EP3977480A1
- [TechCrunch, 2013] Dachis Group, The Social Analytics Startup Led By Razorfish Co-Founder Jeff Dachis, Raises $7.5M More | https://techcrunch.com/2013/03/20/dachis-group-raises-7-5m-to-expand-its-big-data-social-analytics-platform/
- [TechCrunch, 2010] Dachis Continues To Shop For Facebook Preferred Developers, Buys Archrival | https://techcrunch.com/2010/11/17/dachis-group-archrival/
- [LinkedIn] One Health Biosensing company page | https://www.linkedin.com/company/one-health-biosensing
Articles about One Health Biosensing
- One Health Biosensing Wants a Glucose Sensor on Every Wrist That Cannot Afford One — Repeat founder Jeffrey Dachis is back with a pre-seed bet on a low-cost CGM, leaning on a 50-patent portfolio carried over from One Drop.